| D009538 |
Nicotine |
Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. |
Nicotine Bitartrate,Nicotine Tartrate |
|
| D011582 |
Psychological Theory |
Principles applied to the analysis and explanation of psychological or behavioral phenomena. |
Social Cognitive Theory,Psychologic Theory,Psychological Theories,Theories, Psychological,Theory, Psychological,Cognitive Theories, Social,Cognitive Theory, Social,Psychologic Theories,Social Cognitive Theories,Theories, Psychologic,Theories, Social Cognitive,Theory, Psychologic,Theory, Social Cognitive |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000074606 |
Smoking Prevention |
Efforts directed at preventing SMOKING of TOBACCO and non-tobacco products. |
Anti-Smoking Campaign,Anti-Smoking Education,Anti Smoking Campaign,Anti Smoking Education,Anti-Smoking Campaigns,Anti-Smoking Educations,Campaign, Anti-Smoking,Campaigns, Anti-Smoking,Education, Anti-Smoking,Prevention, Smoking,Preventions, Smoking,Smoking Preventions |
|
| D012907 |
Smoking |
Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. |
Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits |
|
| D016540 |
Smoking Cessation |
Discontinuing the habit of SMOKING. |
Giving Up Smoking,Quitting Smoking,Stopping Smoking,Cessation, Smoking,Smoking Cessations,Smoking, Giving Up,Smoking, Quitting,Smoking, Stopping,Smokings, Giving Up,Up Smoking, Giving |
|
| D017410 |
Practice Guidelines as Topic |
Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. |
Clinical Guidelines as Topic,Best Practices,Best Practice |
|
| D061485 |
Tobacco Use Cessation Devices |
Devices or delivery systems used to aid in ending a TOBACCO habit. |
Tobacco Use Cessation Products,Nicotine Delivery Devices,Nicotine Inhalant,Nicotine Lozenge,Nicotine Lozenges,Nicotine Nasal Spray,Nicotine Patch,Nicotine Polacrilex,Nicotine Replacement Products,Nicotine Transdermal Patch,Smoking Cessation Products,Delivery Device, Nicotine,Delivery Devices, Nicotine,Device, Nicotine Delivery,Devices, Nicotine Delivery,Inhalant, Nicotine,Inhalants, Nicotine,Lozenge, Nicotine,Lozenges, Nicotine,Nasal Spray, Nicotine,Nasal Sprays, Nicotine,Nicotine Delivery Device,Nicotine Inhalants,Nicotine Nasal Sprays,Nicotine Replacement Product,Patch, Nicotine,Patch, Nicotine Transdermal,Polacrilex, Nicotine,Product, Nicotine Replacement,Product, Smoking Cessation,Products, Nicotine Replacement,Products, Smoking Cessation,Replacement Product, Nicotine,Replacement Products, Nicotine,Smoking Cessation Product,Spray, Nicotine Nasal,Sprays, Nicotine Nasal,Transdermal Patch, Nicotine |
|
| D018722 |
Nicotinic Agonists |
Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. |
Cholinergic Agonists, Nicotinic,Cholinergic Agonist, Nicotinic,Nicotinic Agonist,Agonist, Nicotinic,Agonist, Nicotinic Cholinergic,Agonists, Nicotinic,Agonists, Nicotinic Cholinergic,Nicotinic Cholinergic Agonist,Nicotinic Cholinergic Agonists |
|
| D040261 |
Harm Reduction |
The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors. |
Harm Minimization,Minimization, Harm,Reduction, Harm |
|